Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 23, 2022 07:30 ET | Source: Xilio Therapeutics, Inc.

Xilio Therapeutics to Host Live Virtual Program Spotlighting XTX301, a Tumor-Activated IL-12

WALTHAM, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer,...
November 09, 2022 07:30 ET | Source: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results

XTX202, a tumor-activated IL‑2, successfully reached target dose range of 1 mg/kg in ongoing Phase 1 clinical trial; preliminary evidence of increased CD8+ effector T cells and NK cells observed with...
November 04, 2022 07:30 ET | Source: Xilio Therapeutics, Inc.

Xilio Therapeutics to Present at Cowen 6th Annual ‘IO Next’ Summit

WALTHAM, Mass., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer,...
September 22, 2022 16:05 ET | Source: Xilio Therapeutics, Inc.

Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference

WALTHAM, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer,...
September 15, 2022 16:05 ET | Source: Xilio Therapeutics, Inc.

Xilio Therapeutics Appoints Tomas J. Heyman to Board of Directors

WALTHAM, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer,...
September 06, 2022 16:05 ET | Source: Xilio Therapeutics, Inc.

Xilio Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference

WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer,...
August 09, 2022 07:30 ET | Source: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Encouraging Preliminary Phase 1 Dose-Escalation Data for XTX101, a Tumor-Selective Anti-CTLA-4, and Reports Pipeline and Business Updates and Second Quarter 2022 Financial Results

XTX101, tumor-selective anti-CTLA-4, has successfully reached dose levels exceeding the target dose with limited active (unmasked) molecule in the periphery in ongoing Phase 1 clinical trial ...
June 16, 2022 07:30 ET | Source: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Promotion of Martin Huber, M.D., to President

Paul Clancy Elected as Chair of the Board of Directors Robert Ross, M.D., Appointed to Board of Directors WALTHAM, Mass., June 16, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO),...
May 18, 2022 07:30 ET | Source: Xilio Therapeutics, Inc.

Xilio Therapeutics to Present at the H.C. Wainwright Global Investment Conference

WALTHAM, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer,...
May 17, 2022 07:30 ET | Source: Xilio Therapeutics, Inc.

Xilio Therapeutics Appoints Stacey Davis as Chief Business Officer

WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer,...